Spectrum Pharmaceuticals Stock Forecast, Price & News

-0.09 (-2.80 %)
(As of 08/4/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.66 million shs
Average Volume2.56 million shs
Market Capitalization$513.65 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Spectrum Pharmaceuticals logo

About Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include ROLONTIS, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Henderson, Nevada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.28 out of 5 stars

Medical Sector

264th out of 1,311 stocks

Pharmaceutical Preparations Industry

130th out of 647 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

Is Spectrum Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Spectrum Pharmaceuticals stock.
View analyst ratings for Spectrum Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Spectrum Pharmaceuticals?

Wall Street analysts have given Spectrum Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Spectrum Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Spectrum Pharmaceuticals' next earnings date?

Spectrum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Spectrum Pharmaceuticals

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) posted its earnings results on Thursday, May, 13th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.08.
View Spectrum Pharmaceuticals' earnings history

How has Spectrum Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Spectrum Pharmaceuticals' stock was trading at $2.39 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SPPI stock has increased by 31.0% and is now trading at $3.13.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SPPI?

3 brokers have issued 1-year target prices for Spectrum Pharmaceuticals' shares. Their forecasts range from $8.00 to $12.00. On average, they anticipate Spectrum Pharmaceuticals' stock price to reach $10.67 in the next year. This suggests a possible upside of 240.8% from the stock's current price.
View analysts' price targets for Spectrum Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the following people:
  • Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 63, Pay $1.42M)
  • Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 53, Pay $953.39k)
  • Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 45, Pay $1.03M)
  • Mr. Keith M. McGahan J.D., L.L.M., Exec. VP, Chief Legal Officer & Corp. Sec. (Age 45, Pay $842.19k)
  • Dr. Francois J. Lebel FRCPC, M.D., Exec. VP & Chief Medical Officer (Age 69, Pay $926.76k)
  • Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations
  • Mr. Bimal R. Shah, VP of Corp. & Bus. Devel.
  • Mr. Alberto Dejesus, VP of Marketing
  • Ms. Lisa A. Croissant, VP of Sales
  • Dr. Zane Yang M.D., Sr. VP of Clinical Devel.

What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO?

2 employees have rated Spectrum Pharmaceuticals CEO Joseph Turgeon on Joseph Turgeon has an approval rating of 47% among Spectrum Pharmaceuticals' employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Spectrum Pharmaceuticals' key competitors?

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE).

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (0.15%), Texas Permanent School Fund (0.07%), State of Alaska Department of Revenue (0.07%), Oregon Public Employees Retirement Fund (0.04%), Private Wealth Advisors LLC (0.03%) and Advisor Group Holdings Inc. (0.03%). Company insiders that own Spectrum Pharmaceuticals stock include Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Seth H Z Fischer, Thomas J Riga and William Ashton.
View institutional ownership trends for Spectrum Pharmaceuticals

Which institutional investors are selling Spectrum Pharmaceuticals stock?

SPPI stock was sold by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank . Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Seth H Z Fischer, and Thomas J Riga.
View insider buying and selling activity for Spectrum Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Spectrum Pharmaceuticals stock?

SPPI stock was bought by a variety of institutional investors in the last quarter, including Private Wealth Advisors LLC, Alliancebernstein L.P., Advisor Group Holdings Inc., State of Alaska Department of Revenue, Texas Permanent School Fund, and Oregon Public Employees Retirement Fund.
View insider buying and selling activity for Spectrum Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $3.13.

How much money does Spectrum Pharmaceuticals make?

Spectrum Pharmaceuticals has a market capitalization of $513.65 million and generates $109.33 million in revenue each year. The biotechnology company earns $-160,870,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

How many employees does Spectrum Pharmaceuticals have?

Spectrum Pharmaceuticals employs 175 workers across the globe.

When was Spectrum Pharmaceuticals founded?

Spectrum Pharmaceuticals was founded in 2002.

What is Spectrum Pharmaceuticals' official website?

The official website for Spectrum Pharmaceuticals is

Where are Spectrum Pharmaceuticals' headquarters?

Spectrum Pharmaceuticals is headquartered at 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.